help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arbogast, L. A.
Right arrow Articles by Ben-Jonathan, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arbogast, L. A.
Right arrow Articles by Ben-Jonathan, N.

Endocrinology, Vol 123, 2690-2695, Copyright © 1988 by Endocrine Society


ARTICLES

The preovulatory prolactin surge: an evaluation of the role of dopamine

LA Arbogast and N Ben-Jonathan
Department of Physiology and Biophysics, Indiana University School of Medicine, Indianapolis 46223.

This study examined the contribution of dopamine (DA) to the control of PRL secretion during the preovulatory PRL surge. Immature female rats were injected with PMSG on day 28. At selected times during the periovulatory period, rats were injected with different pharmacological agents, and jugular blood was collected at frequent intervals. Blood PRL levels in vehicle-treated rats were low on the morning of day 30, rose 15- to 20-fold to peak levels from 1400-1500 h, were maintained at a plateau from 1900-2300 h, and were reduced to basal levels on the morning of day 31. Haloperidol, a DA antagonist, induced a 20-fold rise in PRL before the surge, a 2-fold rise above peak PRL levels at 1500 h, and a 50-fold rise on the morning of day 31. In contrast, haloperidol failed to alter PRL release during the plateau phase. Apomorphine, a DA agonist, reduced PRL levels when injected during either the peak or the plateau phase. Injection of 5-hydroxytryptophan, a serotonin precursor, increased PRL levels at all times examined. Anterior pituitary PRL content was reduced to 30% and 10% of the presurge level during the peak and plateau phases, respectively, but increased on the morning of day 31. Basal PRL release by hemipituitaries incubated in vitro paralleled the anterior pituitary PRL content, with markedly less PRL secreted during the peak and plateau phases compared to the presurge period. However, the percent inhibition of PRL release by hemipituitaries incubated with 50 nM DA was similar at all times tested. These data indicate that the peak PRL surge occurs in spite of DA input to the anterior pituitary, a continued responsiveness to DA inhibition, and a diminishing pituitary PRL content. We conclude that a nondopaminergic mechanism, possibly involving a PRL-releasing factor, is responsible for the peak. The plateau phase probably results from an absence of DA input to the anterior pituitary together with a reduction in the releasable pool of PRL. The termination of the PRL surge is caused by the restoration of DA input.


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
N. Ben-Jonathan and R. Hnasko
Dopamine as a Prolactin (PRL) Inhibitor
Endocr. Rev., December 1, 2001; 22(6): 724 - 763.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy
Prolactin: Structure, Function, and Regulation of Secretion
Physiol Rev, October 1, 2000; 80(4): 1523 - 1631.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society